Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature

Rhabdomyosarcoma (RMS) occurs rarely in adults and constitutes 2-6% of all uterine neoplasms. The authors report the case of a 26-year-old woman diagnosed with botryoid RMS that presented discordant progression results on follow up imaging and cytodifferentiation on pathologic control. This case showed that radiological evaluation could be misleading as the tumor demonstrated chemotherapy-induced differentiation without volume reduction. This case illustrates the limitations of using the imaging anatomical dimensions of sarcomas for treatment planning and highlights the potential role of functional imaging to assess the response to treatment.

Chemotherapy; Botryoid rhabdomyosarcoma; Cervix; Cytodifferentiation.

[1] Soliman H., Ferrari A., Thomas D.: “Sarcoma in the young adult population: an international view”. Semin. Oncol., 2009, 36, 227.

[2] Li R.F., Gupta M., McCluggage W.G., Ronnett B.M.: “Embryonal rhabdomyosarcoma (botryoid type) of the uterine corpus and cervix in adult women: report of a case series and review of the literature”. Am. J. Surg. Pathol., 2013, 37, 344.

[3] Behtash N., Mousavi A., Tehranian A., Khanafshar N., Hanjani P.: “Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature”. Gynecol. Oncol., 2003, 91, 452.

[4] Miki Y., Ngan S., Clark J.C.M., Akiyama T., Choong P.F.M.: “The significance of size change of soft tissue sarcoma during preoperative radiotherapy”. Eur. J. Surg. Oncol., 2010, 36, 678.

[5] Fletcher C., Bridge J., Hogendroom P., Mertrens F.: “WHO classification of tumours of soft tissue and bone”. Lyon: IARC, 2013.

[6] Palazzo J.P., Gibas Z., Dunton C.J., Talerman A.: “Cytogenetic study of botryoid rhabdomyosarcoma of the uterine cervix”. Virchows Arch. A. Pathol. Anat. Histopathol., 1993, 422, 87.

[7] Maurer H.M., Crist W., Lawrence W., Ragab A.H., Raney R.B., Webber B., et al.: “The intergroup rhabdomyosarcoma study-I. A final report”. Cancer, 1988, 61, 209.

[8] Kriseman M.L., Wang W.L., Sullinger J., Schmeler K.M., Ramirez P.T., Herzog C.E., et al.: “Rhabdomyosarcoma of the cervix in adult women and younger patients”. Gynecol. Oncol., 2012, 126, 351.

[9] Arndt C.A., Donaldson S.S., Anderson J.R., Andrassy R.J., Laurie F., Link M.P., et al.: “What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?” Cancer, 2001, 91, 2454.

[10] Gwyther S.J., Schwartz L.H.: “How to assess anti-tumour efficacy by imaging techniques”. Eur. J. Cancer. Oxf. Engl., 1990, 2008 44, 39.

[11] Flueckiger F., Ebner F., Poschauko H., Tamussino K., Einspieler R., Ranner G.: “Cervical cancer: serial MR imaging before and after primary radiation therapy—a 2-year follow-up study”. Radiology, 1992, 184, 89.

[12] Jeong Y.Y., Kang H.K., Chung T.W., Seo J.J., Park J.G.: “Uterine cervical carcinoma after therapy: CT and MR imaging findings”. Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc., 2003, 23, 969.

[13] Manfredi R., Maresca G., Smaniotto D., Greggi S., Andrulli D., Rabitti C., et al.: “Cervical cancer response to neoadjuvant therapy: MR imaging assessment”. Radiology, 1998, 209, 819.

[14] Coffin C.M., Lowichik A., Zhou H.: “Treatment effects in pediatric soft tissue and bone tumors practical considerations for the pathologist”. Am. J. Clin. Pathol., 2005, 123, 75.

[15] Lowichik A., Zhou H., Pysher T.J., Smith L., Lemons R., Coffin C.M.: “Therapy associated changes in childhood tumors”. Adv. Anat. Pathol., 2000, 7, 341.

[16] d’Amore E.S., Tollot M., Stracca-Pansa V., Menegon A., Meli S., Carli M., et al.: “Therapy associated differentiation in rhabdomyosarcomas”. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc., 1994, 7, 69.

[17] Coffin C.M., Rulon J., Smith L., Bruggers C., White F.V.: “Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis”. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc., 1997, 10, 1175.

[18] Smith L.M., Anderson J.R., Coffin C.M.: “Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS)”. Med. Pediatr. Oncol., 2002, 38, 398.

[19] Ortega J.A., Rowland J., Monforte H., Malogolowkin M., Triche T.: “Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for the outcome”. J. Pediatr. Hematol. Oncol., 2000, 22, 106.

[20] Zeisler H., Mayerhofer K., Joura E.A., Bancher-Todesca D., Kainz C., Breitenecker G., et al.: “Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature”. Gynecol. Oncol., 1998, 69, 78.